MCDA Hemlibra® in haemophilia A without inhibitors

//MCDA Hemlibra® in haemophilia A without inhibitors

MCDA Hemlibra® in haemophilia A without inhibitors

Determining the value contribution of emicizumab (hemlibra®) for the prophylaxis of haemophilia A patients without inhibitors in Spain by multi-criteria decision analysis (MCDA)

Avaliable at: https://economiadelasalud.com/tag/haemophilia-a/

2020-09-23T17:26:42+00:00May 18th, 2020|Articles|